Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
08. Dezember 2020 06:00 ET
|
Axsome Therapeutics, Inc.
68% reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4 Resolution of suicidal ideation achieved by 60% of patients by Week 1, and 78% by Week 4 Effects consistent with...